Glaukos Co. (NYSE:GKOS) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Glaukos Co. (NYSE:GKOS) by 36.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,939 shares of the medical instruments supplier’s stock after acquiring an additional 3,983 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Glaukos were worth $2,240,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets increased its holdings in Glaukos by 186.9% in the third quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock valued at $1,788,000 after buying an additional 8,942 shares during the last quarter. First Turn Management LLC purchased a new position in Glaukos in the third quarter valued at $12,520,000. Harbor Capital Advisors Inc. purchased a new position in shares of Glaukos during the fourth quarter worth about $3,679,000. Victory Capital Management Inc. grew its holdings in shares of Glaukos by 421.8% during the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock worth $10,320,000 after purchasing an additional 64,031 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after purchasing an additional 98,109 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Activity at Glaukos

In other news, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,744 shares of company stock worth $2,504,131 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $102.43 on Monday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market cap of $5.79 billion, a P/E ratio of -35.69 and a beta of 0.99. Glaukos Co. has a 52 week low of $85.04 and a 52 week high of $163.71. The company has a 50-day moving average price of $140.86 and a 200 day moving average price of $137.69.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Research analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on GKOS. Stephens raised Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group began coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. BTIG Research raised their price objective on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th. Finally, Needham & Company LLC raised their price objective on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.